To assess the consequences of NLRP3-inflammasome and caspase-1 activation in COVID-19 patients, we measured the levels of IL-1β, IL-1Ra and IL-6 in both BALF and serum of C-ARDS or NC-ARDS patients and in control subjects. This evidence concerns the gene CASP1 and COVID-19.